WCN26-5543 EFFICACY OF ATRASENTAN BY RENIN–ANGIOTENSIN SYSTEM INHIBITOR DOSE IN IgA NEPHROPATHY PATIENTS FROM EAST ASIA: POST HOC ANALYSIS FROM THE PHASE III ALIGN TRIAL

Read full text Summarise with VIRAT
Authors: Hong Zhang, Jonathan Barratt, Hiddo J.L. Heerspink, Meg Jardine, Donald E. Kohan, Adeera Levin, Adrian Liew, Suparna Mallik, Ankit Bharat Patel, Elena Morris, Yuhan Li, Marion Dahlke
+1 more Richard A. Lafayette
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Atrasentan is a highly potent and highly selective endothelin A receptor antagonist that is being investigated alongside existing renin–angiotensin system inhibitor (RASi) treatment in patients (pts) with IgA nephropathy (IgAN). At the prespecified Week (W) 36 interim analysis of the Phase III ALIGN trial (NCT04573478), atrasentan led to a statistically significant and clinically meaningful 36.1% reduction in the primary endpoint of 24-hour urine protein–creatinine ratio (24h-UPCR) vs placebo; results were consistent regardless of baseline (BL) RASi dose.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renin-Angiotensin System Studies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106247–106247
Publication date
25 March 2026
Language
EN